EGFR and endometrial carcinoma: Interestingly, in early work by Niikura et al., it was reported that immunostaining of EGFR was found for 58% of normal endometrial biopsies, 100% of endometrial hyperplasia and about 67% of endometrial carcinoma specimens, which most probably indicates that both normal and abnormal endometria are heterogeneous in terms of EGFR expression [53].